Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus ZEGERID OTC.
PANTOPRAZOLE SODIUM vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Renal (80% as metabolites) and fecal (20%)
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor